利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.019 秒)

    Tumor-specific P450 protein
    1.
    发明授权
    Tumor-specific P450 protein 有权
    肿瘤特异性P450蛋白

    公开(公告)号：US06242203B1

    公开(公告)日：2001-06-05

    申请号：US09043814

    申请日：1999-01-22

    申请人： William Thomas Melvin ,  Graeme Ian Murray ,  Michael Danny Burke ,  William Frank Greenlee

    发明人： William Thomas Melvin ,  Graeme Ian Murray ,  Michael Danny Burke ,  William Frank Greenlee

    IPC分类号： G01N3353

    CPC分类号： A61K38/44 ,  C12N9/0077 ,  C12Q1/26 ,  C12Y114/14001 ,  G01N33/57492 ,  G01N2333/90245 ,  G01N2500/00

    摘要： The discovery that Cyp1B1 protein is detectable in a wide range of human cancers of different histogenetic types, but is not detectable in non-cancerous tissues, gives rise to diagnostic methods for detecting tumors based on this protein as a marker, and to the possibility of tumor therapies involving the protein. A diagnostic method may include the steps of: (a) obtaining from a patient a tissue sample to be tested for the presence of cancer cells; (b) producing a prepared sample in a sample preparation process; (c) contacting the prepared sample with an antibody that reacts with human Cyp1B1 protein; and (d) detecting binding of the antibody to CYP1B1 protein in the prepared sample.

    摘要翻译： Cyp1B1蛋白在广泛的不同组织发生型人类癌症中可检测到但在非癌组织中无法检测到的发现产生了用于基于该蛋白质作为标记物检测肿瘤的诊断方法，以及可能性 涉及蛋白质的肿瘤治疗。 诊断方法可以包括以下步骤：（a）从患者获得要测试的癌细胞的存在的组织样品; （b）在样品制备过程中制备制备的样品; （c）使制备的样品与与人Cyp1B1蛋白反应的抗体接触; 和（d）检测所制备样品中抗体与CYP1B1蛋白的结合。

    CANCER MARKERS
    2.
    发明申请
    CANCER MARKERS 审中-公开
    癌症标志

    公开(公告)号：US20100216156A1

    公开(公告)日：2010-08-26

    申请号：US12707700

    申请日：2010-02-18

    申请人： Graeme Ian Murray ,  Colin Matheson Telfer ,  William Thomas Melvin

    发明人： Graeme Ian Murray ,  Colin Matheson Telfer ,  William Thomas Melvin

    IPC分类号： G01N33/574 ,  C12Q1/02

    CPC分类号： G01N33/57419 ,  G01N2800/52

    摘要： Provided are previously uncharacterized markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO:1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—STI1; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO:10—mortalin; and SEQ ID NO:11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues.

    摘要翻译： 提供了癌症的先前未表征的标志物，例如结肠直肠癌，以及它们作为癌症的诊断和预后标志物，特别是结肠直肠癌的用途。 标记是SEQ ID NO：1-hnRNP-K; SEQ ID NO：2-HMG-1; SEQ ID NO：3-蛋白酶体亚型α1型; SEQ ID NO：4-双功能嘌呤生物合成蛋白; SEQ ID NO：5-STI1; IV中的SEQ ID NO：6-附件; SEQ ID NO：7-60 kDa热休克蛋白; SEQ ID NO：8-T复合蛋白1β亚基; SEQ ID NO：9-T复合蛋白1ε亚基; SEQ ID NO：10-mortalin; 和SEQ ID NO：11-TER-ATP酶。 本发明还提供了用于在结肠直肠癌和其他癌症中的治疗性干预中使用标志物的相关方法和材料。 以特异性靶向肿瘤细胞而不在健康组织中引起显着的毒性，并提供评估候选治疗化合物调节结肠，直肠和其他组织中癌细胞的生物学活性的能力的方法。

    Mitochondrial stress-70 protein markers for colorectal cancer
    3.
    发明授权
    Mitochondrial stress-70 protein markers for colorectal cancer 失效
    线粒体应激70蛋白标记物用于结肠直肠癌

    公开(公告)号：US07700307B2

    公开(公告)日：2010-04-20

    申请号：US10548694

    申请日：2004-03-08

    申请人： Graeme Ian Murray ,  Colin Matheson Telfer ,  William Thomas Melvin

    发明人： Graeme Ian Murray ,  Colin Matheson Telfer ,  William Thomas Melvin

    IPC分类号： G01N33/574 ,  G01N33/53

    CPC分类号： G01N33/57419 ,  G01N2800/52

    摘要： Provided are previously uncharacterised markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO: 1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—ST11; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO: 10—mortalin; and SEQ ID NO: 11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues.

    摘要翻译： 提供了先前未表征的癌症标志物，例如结肠直肠癌，以及它们作为癌症，特别是结肠直肠癌的诊断和预后标志物的用途。 标记是SEQ ID NO：1-hnRNP-K; SEQ ID NO：2-HMG-1; SEQ ID NO：3-蛋白酶体亚型α1型; SEQ ID NO：4-双功能嘌呤生物合成蛋白; SEQ ID NO：5〜ST11; IV中的SEQ ID NO：6-附件; SEQ ID NO：7-60 kDa热休克蛋白; SEQ ID NO：8-T复合蛋白1β亚基; SEQ ID NO：9-T复合蛋白1ε亚基; SEQ ID NO：10-mortalin; 和SEQ ID NO：11-TER-ATP酶。 本发明还提供了用于在结肠直肠癌和其他癌症中的治疗性干预中使用标志物的相关方法和材料。 以特异性靶向肿瘤细胞而不在健康组织中引起显着的毒性，并提供评估候选治疗化合物调节结肠，直肠和其他组织中癌细胞的生物学活性的能力的方法。